MedTrace Logo

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

NCT02784795 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2025-08-21

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.

Conditions

Interventions

DRUG

LY3039478

Administered orally

DRUG

Taladegib

Administered orally

DRUG

Abemaciclib

Administered orally

DRUG

Cisplatin

Administered IV

DRUG

Gemcitabine

Administered IV

DRUG

Carboplatin

Administered IV

DRUG

LY3023414

Administered orally

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-04
Primary Completion
2018-08-09
Completion
2020-02-13

Countries

  • United States
  • Denmark
  • France
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02784795 on ClinicalTrials.gov